Trial Profile
A Multicenter Uncontrolled Extension Study Evaluating the Long Term Safety and Efficacy of SAR153191 in Patients With Ankylosing Spondylitis (AS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Oct 2021
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications Ankylosing spondylitis
- Focus Adverse reactions
- Acronyms SUSTAIN
- Sponsors Sanofi
- 14 Oct 2021 This trial has been completed in France (Global end date: 12 Dec 2011).